Top

International Urology and Nephrology

Published in:

01-11-2021 | Erectile Dysfunction | Urology - Original Paper

Relationship between erectile dysfunction and moderate to severe prostatitis-like symptoms in middle-aged men: a propensity score–matched analysis

Authors: Jun Ho Lee, Tag Keun Yoo, Jung Yoon Kang, Jeong Man Cho, Yeon Won Park, Sin Woo Lee, Jae Duck Choi

Published in: International Urology and Nephrology | Issue 11/2021

Abstract

Purpose

We assessed the relationship between chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and erectile dysfunction (ED) using propensity score matching.

Methods

Data from 8727 middle-aged men who had undergone health checkups were analyzed. The National Institutes of Health Chronic Prostatitis Symptoms Index (NIH-CPSI), the International Index of Erectile Function-5 (IIEF), the Premature Ejaculation Diagnostic Tool (PEDT), testosterone measurement, basic blood chemistry, and metabolic syndrome (MetS) assessment were performed in this study. Of the 8727 men considered, 7181 formed the cohort for propensity score matching, including 597 men with moderate to severe prostatitis-like symptoms (case) and 6584 men with no prostatitis-like symptoms (control); ultimately, however, members of the case and control groups were matched at a 1:1 ratio by propensity score.

Results

After matching, the variables of age, testosterone, PEDT and MetS were evenly distributed between the groups. After matching, the mean IIEF score of the case group was significantly lower than that of the control group (17.2 ± 5.5 vs. 14.7 ± 5.3; P < 0.001). Additionally, the severity of ED was significantly greater in the case group (no, mild, mild to moderate, moderate, and severe, respectively: 27.5%, 30.2%, 24.6%, 13.1%, and 4.7% in the control group; 10.7%, 27.0%, 33.0%, 18.9%, and 10.4% in the case group; P < 0.001). Finally, the rate of moderate to severe ED was significantly higher in the case group than in the control group (17.8% vs. 29.3%; P < 0.001).

Conclusion

Moderate to severe prostatitis-like symptoms were significantly and independently correlated with ED in middle-aged men.

Krieger JN, Egan KJ, Ross SO, Jacobs R, Berger RE (1996) Chronic pelvic pains represent the most prominent urogenital symptoms of chronic prostatitis. Urology 48(5):715–721. https://doi.org/10.1016/S0090-4295(96)00421-9 (Discussion 721–712)CrossRefPubMed

Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE (2008) Epidemiology of prostatitis. Int J Antimicrob Agents 31(Suppl 1):S85-90. https://doi.org/10.1016/j.ijantimicag.2007.08.028CrossRefPubMed

Pavone-Macaluso M (2007) Chronic prostatitis syndrome: a common, but poorly understood condition. Part I. Eau-Ebu Updat Ser 5(1):1–15CrossRef

Gonen M, Kalkan M, Cenker A, Ozkardes H (2005) Prevalence of premature ejaculation in Turkish men with chronic pelvic pain syndrome. J Androl 26(5):601–603. https://doi.org/10.2164/jandrol.04159CrossRefPubMed

Sonmez NC, Kiremit MC, Guney S, Arisan S, Akca O, Dalkilic A (2011) Sexual dysfunction in type III chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) observed in Turkish patients. Int Urol Nephrol 43(2):309–314. https://doi.org/10.1007/s11255-010-9809-5CrossRefPubMed

Tan JK, Png DJ, Liew LC, Li MK, Wong ML (2002) Prevalence of prostatitis-like symptoms in Singapore: a population-based study. Singapore Med J 43(4):189–193PubMed

Hao ZY, Li HJ, Wang ZP, Xing JP, Hu WL, Zhang TF, Zhang XS, Zhou J, Tai S, Liang CZ (2011) The prevalence of erectile dysfunction and its relation to chronic prostatitis in Chinese men. J Androl 32(5):496–501. https://doi.org/10.2164/jandrol.110.012138CrossRefPubMed

Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, Gontero P, Gavazzi A, Giubilei G, Prezioso D, Mazzoli S, Boddi V, Naber KG, Italian Prostatitis Study G (2007) Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 178(6):2411–2415. https://doi.org/10.1016/j.juro.2007.08.046 (Discussion 2415)CrossRefPubMed

Rosen RC, Link CL, O’Leary MP, Giuliano F, Aiyer LP, Mollon P (2009) Lower urinary tract symptoms and sexual health: the role of gender, lifestyle and medical comorbidities. BJU Int 103(Suppl 3):42–47. https://doi.org/10.1111/j.1464-410X.2009.08370.xCrossRefPubMed

10.

Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh J, Khera M, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW (2018) Erectile dysfunction: AUA guideline. J Urol 200(3):633–641. https://doi.org/10.1016/j.juro.2018.05.004CrossRefPubMed

11.

Evans DT, Jaleel H, Keefe A (2007) Retrospective review of clinical practice in chronic pelvic pain syndrome ie category III chronic prostatitis at two hospital sites over five years 2000–2005 (an audit). Int J STD AIDS 18(4):276–280. https://doi.org/10.1258/095646207780658917CrossRefPubMed

12.

Stamatiou K, Magri V, Perletti G, Samara E, Christopoulos G, Trinchieri A (2020) How urologists deal with chronic prostatitis? The preliminary results of a Mediterranean survey. Arch Ital Urol Androl. https://doi.org/10.4081/aiua.2020.4.353CrossRefPubMed

13.

Lee JH, Lee SW (2015) Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. J Sex Med 12(3):697–704CrossRef

14.

Nickel JC, Downey J, Hunter D, Clark J (2001) Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 165(3):842–845CrossRef

15.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404CrossRef

16.

Tran CN, Shoskes DA (2013) Sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. World J Urol 31(4):741–746. https://doi.org/10.1007/s00345-013-1076-5CrossRefPubMed

17.

Chung SD, Keller JJ, Lin HC (2012) A case-control study on the association between chronic prostatitis/chronic pelvic pain syndrome and erectile dysfunction. BJU Int 110(5):726–730. https://doi.org/10.1111/j.1464-410X.2011.10807.xCrossRefPubMed

18.

Ku JH, Kim SW, Paick JS (2005) Epidemiologic risk factors for chronic prostatitis. Int J Androl 28(6):317–327. https://doi.org/10.1111/j.1365-2605.2005.00560.xCrossRefPubMed

19.

Elbendary MA, El-Gamal OM, Salem KA (2009) Analysis of risk factors for organic erectile dysfunction in Egyptian patients under the age of 40 years. J Androl 30(5):520–524. https://doi.org/10.2164/jandrol.108.007195CrossRefPubMed

20.

Mulhall JP, Luo X, Zou KH, Stecher V, Galaznik A (2016) Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int J Clin Pract 70(12):1012–1018. https://doi.org/10.1111/ijcp.12908CrossRefPubMedPubMedCentral

21.

Thomas DD, Corkey BE, Istfan NW, Apovian CM (2019) Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc 3(9):1727–1747. https://doi.org/10.1210/js.2019-00065CrossRefPubMedPubMedCentral

22.

Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, Cipriani S, Gacci M, Forti G, Maggi M (2014) Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl 16(2):295–304. https://doi.org/10.4103/1008-682X.122341CrossRefPubMedPubMedCentral

23.

Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M (2013) Fat boosts, while androgen receptor activation counteracts. BPH-associated prostate inflammation. Prostate 73(8):789–800. https://doi.org/10.1002/pros.22623CrossRefPubMed

24.

Lee JH, Lee SW (2016) Testosterone and chronic prostatitis/chronic pelvic pain syndrome: a propensity score-matched analysis. J Sex Med 13(7):1047–1055. https://doi.org/10.1016/j.jsxm.2016.04.070CrossRefPubMed

25.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424. https://doi.org/10.1080/00273171.2011.568786CrossRef

26.

Marszalek M, Wehrberger C, Hochreiter W, Temml C, Madersbacher S (2007) Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 177(5):1815–1819. https://doi.org/10.1016/j.juro.2007.01.008CrossRefPubMed

27.

Mo MQ, Long LL, Xie WL, Chen S, Zhang WH, Luo CQ, Deng LW (2014) Sexual dysfunctions and psychological disorders associated with type IIIa chronic prostatitis: a clinical survey in China. Int Urol Nephrol 46(12):2255–2261. https://doi.org/10.1007/s11255-014-0810-2CrossRefPubMed

Title: Relationship between erectile dysfunction and moderate to severe prostatitis-like symptoms in middle-aged men: a propensity score–matched analysis
Authors: Jun Ho Lee
Tag Keun Yoo
Jung Yoon Kang
Jeong Man Cho
Yeon Won Park
Sin Woo Lee
Jae Duck Choi
Publication date: 01-11-2021
Publisher: Springer Netherlands
Keywords: Erectile Dysfunction
Prostatitis
Premature Ejaculation
Premature Ejaculation
Testosterone
Published in: International Urology and Nephrology / Issue 11/2021
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-021-02991-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2021

Usefulness of the mayo adhesive probability score as a predictive factor for renal function deterioration after partial nephrectomy: a retrospective case–control study

Serum lactate dehydrogenase level is associated with in-hospital mortality in critically Ill patients with acute kidney injury

Urine versus stent cultures and clinical UTIs

Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial

Letter to the editor re: the effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients Altunan et al., IJUN, (2021) 53:1059

COVID-19 in hemodialysis patients: a single-center experience in Istanbul

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials